Evidence map›Paper›PMID 31910895›Full record

Trial reportAlzheimer's research & therapy2020

Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI.

Jolien F Leijenaar, Geert Jan Groeneveld, Erica S Klaassen, Anna E Leeuwis, Philip Scheltens, Henry C Weinstein, Joop M A van Gerven, Frederik Barkhof, Wiesje M van der Flier, Niels D Prins

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alzheimer's research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02098824 (Symptomatic Treatment of Vascular Cognitive Impairment), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02098824 phase2 / phase3unknown statusnot on this map

Symptomatic Treatment of Vascular Cognitive Impairment

TypeinterventionalSponsorAmsterdam UMC, location VUmcRan2014 to 2017Enrolled30ConditionsMild Cognitive Impairment (Vascular), Mild Cognitive Disorder (Vascular), Vascular DementiaArmsGalantamine, Methylphenidate, Placebo
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Vascular cognitive impairment and dementia: Prevention, treatments, mechanisms and management options for the future.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jolien F LeijenaarAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands. j.leijenaar@amsterdamumc.nl.ORCID 0000-0002-1524-3801
Geert Jan GroeneveldCentre for Human Drug Research, Leiden, The Netherlands.
Erica S KlaassenCentre for Human Drug Research, Leiden, The Netherlands.
Anna E LeeuwisAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands.
Philip ScheltensAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands.
Henry C WeinsteinDepartment of Neurology, Onze Lieve Vrouwe Gasthuis (OLVG) West, Amsterdam, The Netherlands.
Joop M A van GervenCentre for Human Drug Research, Leiden, The Netherlands.
Frederik BarkhofDepartment of Radiology and Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, Amsterdam, The Netherlands.
Wiesje M van der FlierAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands.
Niels D PrinsAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands.
Amsterdam Neuroscience · NLCentre for Human Drug Research · NLOLVG · NL

Funding

Alzheimer Nederland WE.03-2012-02
6 · The paper itself

Abstract

backgroundTo date, no symptomatic treatment is available for patients with vascular cognitive impairment (VCI). In the proof-of-principle study Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI), we investigated whether a single dose of a monoaminergic drug (methylphenidate) improves executive functioning and whether a single dose of a cholinergic drug (galantamine) improves memory in VCI patients.

methodsSTREAM-VCI is a single-center, double-blind, three-way crossover trial. We included 30 VCI patients (Mini-Mental State Examination (MMSE) ≥ 16 and Clinical Dementia Rating score 0.5-1.0) with cerebrovascular pathology on MRI. All patients received single doses of methylphenidate (10 mg), galantamine (16 mg), and placebo in random order on three separate study visits. We used the NeuroCart®, a computerized test battery, to assess drug-sensitive cognitive effects. Predefined main outcomes, measured directly after a single dose of a study drug, were (i) change in performance on the adaptive tracker for executive functioning and (ii) performance on the Visual Verbal Learning Test-15 (VVLT-15) for memory, compared to placebo. We performed mixed model analysis of variance.

resultsThe study population had a mean age of 67 ± 8 years and MMSE 26 ± 3, and 9 (30%) were female. Methylphenidate improved performance on the adaptive tracker more than placebo (mean difference 1.40%; 95% confidence interval [CI] 0.56-2.25; p = 0.002). In addition, methylphenidate led to better memory performance on the VVLT-15 compared to placebo (mean difference in recalled words 0.59; 95% CI 0.03-1.15; p = 0.04). Galantamine did not improve performance on the adaptive tracker and led to worse performance on delayed recall of the VVLT-15 (mean difference - 0.84; 95% CI - 1.65, - 0.03; p = 0.04). Methylphenidate was well tolerated while galantamine produced gastrointestinal side effects in a considerable number of patients.

conclusionsIn this proof-of-principle study, methylphenidate is well tolerated and improves executive functioning and immediate recall in patients with VCI. Galantamine did not improve memory or executive dysfunction. Results might be influenced by the considerable amount of side effects seen.

trial registrationhttp://www.clinicaltrials.gov. Registration number: NCT02098824. Registration date: March 28, 2014.

Indexed as

AgedCentral Nervous System StimulantsCognitive DysfunctionCross-Over StudiesDementia, VascularDouble-Blind MethodExecutive FunctionFemaleGalantamineHumansMaleMemoryMethylphenidateMiddle AgedNootropic AgentsProof of Concept StudyCentral Nervous System StimulantsGalantamineMethylphenidateNootropic AgentsCognitionGalantamineMCIMethylphenidateVascular cognitive impairmentVascular dementia

Identifiers

PMID31910895
PMCPMC6947990
OpenAlexW2999969288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.